Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID A HINCHMAN

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1710914528
CMS profile
122524
Location
BOISE, ID

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$168.75

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $162.65 4
Education $6.10 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $100.72 1
iRhythm Technologies, Inc. $23.69 1
Abbott Laboratories $21.68 1
Amgen Inc. $16.56 1
PFIZER INC. $6.10 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID A HINCHMAN

NPI 1710914528 · CMS profile ID 122524

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

BOISE, ID

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710914528?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID A HINCHMAN, NPI 1710914528, CMS profile ID 122524. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710914528?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAVID A HINCHMAN, NPI 1710914528, CMS profile ID 122524. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710914528?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAVID A HINCHMAN, NPI 1710914528, CMS profile ID 122524, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1710914528?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $168.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $100.7212/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783409387 CMS
Abbott Laboratories $21.6806/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815519359 CMS
Amgen Inc. $16.5605/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825249151 CMS
iRhythm Technologies, Inc. $23.6904/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 831029035 CMS
PFIZER INC. $6.1003/04/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833270161 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $181.14 11
PY2021 $168.75 5
PY2022 $11,464.89 18
PY2023 $71,624.38 127
PY2024 $88,566.54 158
PY2025 $152,409.43 151

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,669.33 1
PY2025 Principal investigator $312,600.42 16
PY2024 Recipient $70,959.20 2
PY2024 Principal investigator $52,849.00 4
PY2023 Principal investigator $65,514.00 33
PY2022 Recipient $13,862.00 1
PY2022 Principal investigator $212,977.69 60
PY2021 Principal investigator $197,207.64 41
PY2020 Principal investigator $175,269.34 38
PY2019 Principal investigator $288,116.48 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $837.90 12/15/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391279
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 11/30/2020 Non-covered Recipient Entity
St Lukes Regl Medcl Ctr
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure No dispute reported 06/30/2026 719522277
Principal investigator 1 Amgen Inc. $6,987.60 11/23/2020 Non-covered Recipient Entity
SAINT LUKES IDAHO CARDIOLOGY ASSOCIATES
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 753887787
Principal investigator 1 CSL Behring $50.00 11/12/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391267
Principal investigator 1 CSL Behring $3,673.80 11/12/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391269
Principal investigator 1 ARRAY BIOPHARMA INC $1,000.00 11/10/2020 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 IN PATIENTS WITH SYMPTOMATIC GENETIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 742899865
Principal investigator 1 Amgen Inc. $776.40 10/13/2020 Non-covered Recipient Entity
SAINT LUKES IDAHO CARDIOLOGY ASSOCIATES
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 753887475
Principal investigator 1 Amgen Inc. $776.40 10/13/2020 Non-covered Recipient Entity
SAINT LUKES IDAHO CARDIOLOGY ASSOCIATES
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 753887477
Principal investigator 1 CSL Behring $250.00 10/06/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391245
Principal investigator 1 CSL Behring $4,775.40 10/06/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391247
Principal investigator 1 ARRAY BIOPHARMA INC $1,000.00 09/22/2020 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 IN PATIENTS WITH SYMPTOMATIC GENETIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 742939571
Principal investigator 1 CSL Behring $150.00 09/10/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391231
Principal investigator 1 CSL Behring $3,848.40 09/10/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391233
Principal investigator 1 CSL Behring $82.40 08/26/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 764635594
Principal investigator 1 CSL Behring $1,031.40 08/11/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391217
Principal investigator 1 CSL Behring $89.40 06/25/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 764635590
Principal investigator 1 CSL Behring $1,000.00 06/02/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391197
Principal investigator 1 CSL Behring $1,000.00 06/02/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391207
Principal investigator 1 CSL Behring $1,000.00 06/02/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391209
Principal investigator 1 Amgen Inc. $8,124.00 05/19/2020 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 731649207
Principal investigator 1 CSL Behring $3,130.20 05/14/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391195
Principal investigator 1 CSL Behring $100.00 04/14/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391177
Principal investigator 1 CSL Behring $1,049.40 04/09/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391175
Principal investigator 1 American Regent $6,963.00 04/08/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
Heart_FID No dispute reported 06/30/2026 737106741
Principal investigator 1 CSL Behring $386.10 03/26/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 764635584
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,274.76 03/25/2020 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) No dispute reported 06/30/2026 721488451
Principal investigator 1 CSL Behring $4,775.40 03/12/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391171
Principal investigator 1 CSL Behring $250.00 03/12/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391173
Principal investigator 1 American Regent $717.00 03/09/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
Heart_FID No dispute reported 06/30/2026 737107399
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,718.00 02/14/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
Exercise capacity study in HFpEF No dispute reported 06/30/2026 751190651
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,733.19 02/14/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
Exercise capacity study in HFrEF No dispute reported 06/30/2026 751190653
Principal investigator 1 CSL Behring $8,453.70 02/13/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391165
Principal investigator 1 CSL Behring $350.00 02/13/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391167
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,335.34 01/29/2020 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
PROSPECTIVE COMPARISON OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR ARNI VERSUS ACE INHIBITOR TRIAL TO DETERMINE IMPACT ON SERIOUS EVENTS AFTER MYOCARDIAL INFARCTION PARADISE MI No dispute reported 06/30/2026 721488449
Principal investigator 1 CSL Behring $450.25 01/28/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 764635582
Principal investigator 1 CSL Behring $693.90 01/09/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391145
Principal investigator 1 CSL Behring $100.00 01/09/2020 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 724391147
Principal investigator 1 Amgen Inc. $69,336.00 01/08/2020 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 731649211